F
F Andreozzi
Researcher at Seconda Università degli Studi di Napoli
Publications - 5
Citations - 419
F Andreozzi is an academic researcher from Seconda Università degli Studi di Napoli. The author has contributed to research in topics: Cancer & Gemcitabine. The author has an hindex of 2, co-authored 5 publications receiving 327 citations.
Papers
More filters
Journal ArticleDOI
Treatment of gastric cancer.
Michele Orditura,Gennaro Galizia,Vincenzo Sforza,Valentina Gambardella,Alessio Fabozzi,Maria Maddalena Laterza,F Andreozzi,Jole Ventriglia,B. Savastano,Andrea Mabilia,Eva Lieto,Fortunato Ciardiello,Ferdinando De Vita +12 more
TL;DR: Recent evidence supports the use of second-line chemotherapy after progression in patients with good performance status, and perioperative and adjuvant chemotherapy, as well as chemoradiation, can improve outcome of resectable gastric cancer with extended lymph node dissection.
Journal ArticleDOI
Advanced/metastatic bladder cancer: current status and future directions.
Gaetano Facchini,Carla Cavaliere,L. Romis,Salvatore Mordente,S Facchini,Gelsomina Iovane,Mario Capasso,D D'Errico,Carmela Liguori,R Formato,S Cicala,F Andreozzi,G Di Lauro,Ciro Imbimbo,M Vanni,Carmine D'Aniello +15 more
TL;DR: The present review provides an update on the management of MBC, with focus on target therapies, immune checkpoint inhibition, looking for prognostic and predictive factors.
Journal ArticleDOI
Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer
Claudia Cardone,Erika Martinelli,Teresa Troiani,Vincenzo Sforza,Antonio Avallone,Anna Nappi,Vincenzo Montesarchio,F Andreozzi,M. Biglietto,Filomena Calabrese,Roberto Bordonaro,Stefano Cordio,Giacomo Bregni,Antonio Febbraro,Rocio Garcia-Carbonero,Jaime Feliu,Andrés Cervantes,Fortunato Ciardiello +17 more
TL;DR: RAVELLO suggests that regorafenib has not a major activity in maintenance setting after upfront chemotherapy and anti-EGFR MoAb in patients with RAS WT mCRC, indicating that a better refinement of the patient population would help to identify subjects that might benefit from a regorAFenib personalised approach in the switch maintenance setting.
Journal ArticleDOI
2335 Analysis of activity, efficacy and safety of first line Nab Paclitaxel (Nab-P) and Gemcitabine (G) in advanced pancreatic cancer (APDAC) frail and elderly patients (pts)
G. Giordano,F. De Vita,Davide Melisi,Vanja Vaccaro,A. Zaniboni,V. Zagonel,Enrico Vasile,Alessandro Passardi,L. Leo,Jole Ventriglia,Roberta Marciano,Marco Russano,R. Conca,F Andreozzi,Eleonora Lucchini,Gianna Musettini,Paola Bertocchi,Francesca Bergamo,M. Milella,Antonio Febbraro +19 more
Journal ArticleDOI
Penile cancer: prognostic and predictive factors in clinical decision-making.
Carmine D'Aniello,Carla Cavaliere,Bianca Arianna Facchini,D D'Errico,Mario Capasso,Gelsomina Iovane,L. Romis,Salvatore Mordente,Carmela Liguori,S Cicala,R Formato,Paola Coppola,F Andreozzi,L. Leo,Vincenzo Montesarchio,G Di Lauro,Salvatore Pisconti,C Di Franco,F De Vita,M Vanni,Gaetano Facchini +20 more
TL;DR: In this paper, the authors summarized the biomarkers of prognosis and efficacy of current treatments with a focus on those that have the potential to affect treatment decision-making in SCPC.